Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Pitt B. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.
2. Pitt B. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
3. Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study. Adv Ther. 2022;39:5158–75.
4. Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus undergoing treatment with sodium-glucose cotransporter 2 inhibitors (EAGLE-DH). Adv Ther. 2023;40:5055–75.
5. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63.